Aurinia Pharmaceuticals to Present at the 9th Annual SVB Leerink Global Healthcare Conference Feb 21, 2020
Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares Dec 12, 2019
Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis Dec 4, 2019
Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil Nov 7, 2019
Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019 Nov 6, 2019
